Income Statement Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
313.41 ^USD	-1.20%		-2.26%	-21.18%

06/03	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement	CI
05/03	Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments	RE

0c291ecf7.qDxR_yPwBiaBWl8VArC_LvoBn9KDiEwuBJY1i1-ENeI.kWQ9hxGZTGPpERFYb4iGeMNFy7Hu3TpnW-Ri4yrgZNTwchWlFrFtReAvLA

Published financial data: ALNYLAM PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	84Cr	103.74Cr	182.83Cr	224.82Cr	371.39Cr
Total Revenues	84Cr	103.74Cr	182.83Cr	224.82Cr	371.39Cr
Cost of Goods Sold, Total	14Cr	17Cr	31Cr	32Cr	68Cr
Gross Profit	70Cr	87Cr	151.79Cr	192.49Cr	303.21Cr
Selling General & Admin Expenses, Total	70Cr	77Cr	80Cr	98Cr	121.07Cr
R&D Expenses	71Cr	88Cr	100.44Cr	112.62Cr	131.98Cr
Other Operating Expenses, Total	141.28Cr	165.37Cr	180.01Cr	210.18Cr	253.05Cr
Operating Income	-71Cr	-79Cr	-28Cr	-18Cr	50Cr
Interest Expense, Total	-14Cr	-16Cr	-12Cr	-14Cr	-25Cr
Interest And Investment Income	15.79L	2.48Cr	9.56Cr	12Cr	11Cr
Net Interest Expenses	-14Cr	-13Cr	-2.57Cr	-1.99Cr	-14Cr
Other Non Operating Income (Expenses)	-5.77Cr	-10Cr	-11Cr	-18Cr	-3.5Cr
EBT, Excl. Unusual Items	-91Cr	-101.71Cr	-42Cr	-37Cr	33Cr
Gain (Loss) On Sale Of Investments	5.57Cr	-3.33Cr	-1.69Cr	-30.22L	-23.06L
Legal Settlements	-	-	-	-	-
Other Unusual Items	-	-7.66Cr	-	-	-
EBT, Incl. Unusual Items	-85Cr	-112.7Cr	-43Cr	-38Cr	32Cr
Income Tax Expense	7L	41.63L	67.25L	-9.92Cr	94.05L
Earnings From Continuing Operations	-85Cr	-113.12Cr	-44Cr	-28Cr	31Cr
Net Income to Company	-85Cr	-113.12Cr	-44Cr	-28Cr	31Cr
Net Income - (IS)	-85Cr	-113.12Cr	-44Cr	-28Cr	31Cr
Net Income to Common Incl Extra Items	-85Cr	-113.12Cr	-44Cr	-28Cr	31Cr
Net Income to Common Excl. Extra Items	-85Cr	-113.12Cr	-44Cr	-28Cr	31Cr
Per Share Items
Net EPS - Basic	-7.2	-9.3	-3.52	-2.18	2.39
Basic EPS - Continuing Operations	-7.2	-9.3	-3.52	-2.18	2.39
Basic Weighted Average Shares Outstanding	12Cr	12Cr	12Cr	13Cr	13Cr
Net EPS - Diluted	-7.2	-9.3	-3.52	-2.18	2.33
Diluted EPS - Continuing Operations	-7.2	-9.3	-3.52	-2.18	2.33
Diluted Weighted Average Shares Outstanding	12Cr	12Cr	12Cr	13Cr	13Cr
Normalized Basic EPS	-4.79	-5.22	-2.08	-1.83	1.55
Normalized Diluted EPS	-4.79	-5.22	-2.08	-1.83	1.51
American Depositary Receipts Ratio (ADR)	0.05	0.05	0.05	0.05	0.05
Supplemental Items
EBITDA	-66Cr	-74Cr	-23Cr	-12Cr	56Cr
EBITA	-71Cr	-79Cr	-28Cr	-18Cr	50Cr
EBIT	-71Cr	-79Cr	-28Cr	-18Cr	50Cr
EBITDAR	-53Cr	-72Cr	-16Cr	-5.45Cr	63Cr
Total Revenues (As Reported)	84Cr	103.74Cr	182.83Cr	224.82Cr	371.39Cr
Effective Tax Rate - (Ratio)	-0.08	-0.37	-1.55	26.29	2.91
Current Domestic Taxes	3L	-	40.22L	16L	19.34L
Current Foreign Taxes	31.54L	55.96L	34.16L	59.44L	96.69L
Total Current Taxes	34.47L	55.96L	74.38L	75.44L	1.16Cr
Deferred Domestic Taxes	-	-	-	-	-
Deferred Foreign Taxes	-27.67L	-14.33L	-7L	-11Cr	-21.98L
Total Deferred Taxes	-27.67L	-14.33L	-7L	-11Cr	-21.98L
Normalized Net Income	-57Cr	-64Cr	-26Cr	-23Cr	20Cr
Interest on Long-Term Debt	14Cr	4.84Cr	1.47Cr	14Cr	25Cr
Supplemental Operating Expense Items
Advertising Expense	-	-	-	2.97Cr	3.6Cr
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	79Cr	88Cr	100.44Cr	112.62Cr	131.98Cr
Net Rental Expense, Total	13Cr	1.76Cr	6.66Cr	6.57Cr	7.44Cr
Imputed Operating Lease Interest Expense	7.64Cr	91.61L	2.44Cr	2.75Cr	5.26Cr
Imputed Operating Lease Depreciation	4.98Cr	84.53L	4.22Cr	3.82Cr	2.17Cr
Stock-Based Comp., R&D Exp. (Total)	6.84Cr	9.22Cr	9.73Cr	13Cr	15Cr
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	9.73Cr	14Cr	12Cr	14Cr	19Cr
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	17Cr	23Cr	22Cr	27Cr	35Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	82Cr	87Cr	81Cr	97Cr	165.72Cr
Short Term Investments	161.56Cr	132.6Cr	162.67Cr	172.81Cr	125.12Cr
Total Cash And Short Term Investments	243.56Cr	219.24Cr	243.94Cr	269.45Cr	290.85Cr
Accounts Receivable, Total	20Cr	24Cr	33Cr	41Cr	78Cr
Other Receivables	-	-	-	-	-
Total Receivables	20Cr	24Cr	33Cr	41Cr	78Cr
Inventory	8.64Cr	13Cr	8.91Cr	7.85Cr	8.27Cr
Prepaid Expenses	8.81Cr	13Cr	13Cr	12Cr	28Cr
Restricted Cash	-	-	-	-	-
Total Current Assets	280.86Cr	269.22Cr	298.27Cr	329.53Cr	405.07Cr
Gross Property Plant And Equipment	87Cr	91Cr	95Cr	96Cr	103.08Cr
Accumulated Depreciation	-14Cr	-17Cr	-22Cr	-27Cr	-32Cr
Net Property Plant And Equipment	73Cr	74Cr	73Cr	69Cr	71Cr
Long-term Investments	-	-	-	-	-
Deferred Tax Assets Long-Term	-	-	-	12Cr	13Cr
Other Long-Term Assets, Total	10Cr	12Cr	12Cr	13Cr	8.16Cr
Total Assets	364.33Cr	354.64Cr	382.99Cr	424Cr	496.63Cr
Liabilities
Accounts Payable, Total	7.34Cr	9.81Cr	5.55Cr	8.84Cr	12Cr
Accrued Expenses, Total	37Cr	51Cr	65Cr	80Cr	82Cr
Current Portion of Long-Term Debt	3.71Cr	4.03Cr	5.5Cr	11Cr	22Cr
Current Portion of Leases	4.05Cr	4.2Cr	4.15Cr	4.19Cr	4.55Cr
Unearned Revenue Current, Total	15Cr	4.21Cr	10Cr	5.55Cr	48.45L
Other Current Liabilities	2.28Cr	3.17Cr	5.83Cr	9.23Cr	26Cr
Total Current Liabilities	70Cr	77Cr	97Cr	118.63Cr	146.63Cr
Long-Term Debt	182.67Cr	226.9Cr	234.3Cr	235.9Cr	247.81Cr
Long-Term Leases	28Cr	26Cr	24Cr	23Cr	23Cr
Unearned Revenue Non Current	15Cr	19Cr	19Cr	-	-
Pension & Other Post Retirement Benefits	43L	-	-	-	-
Other Non Current Liabilities	9.47Cr	21Cr	31Cr	40Cr	75.94L
Total Liabilities	305.51Cr	370.46Cr	405.05Cr	417.29Cr	417.72Cr
Common Stock, Total	12.02L	12.4L	12.59L	12.93L	13.24L
Additional Paid In Capital	605.85Cr	645.45Cr	681.11Cr	738.81Cr	751.05Cr
Retained Earnings	-543.82Cr	-656.93Cr	-700.96Cr	-728.77Cr	-670.25Cr
Comprehensive Income and Other	-3.33Cr	-4.47Cr	-2.34Cr	-3.45Cr	-2.01Cr
Total Common Equity	59Cr	-16Cr	-22Cr	6.71Cr	79Cr
Total Equity	59Cr	-16Cr	-22Cr	6.71Cr	79Cr
Total Liabilities And Equity	364.33Cr	354.64Cr	382.99Cr	424Cr	496.63Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	12Cr	12Cr	13Cr	13Cr	13Cr
ECS Total Common Shares Outstanding	12Cr	12Cr	13Cr	13Cr	13Cr
Book Value / Share	4.89	-1.28	-1.75	0.52	5.96
Tangible Book Value	59Cr	-16Cr	-22Cr	6.71Cr	79Cr
Tangible Book Value Per Share	4.89	-1.28	-1.75	0.52	5.96
Total Debt	218.57Cr	261.26Cr	268.26Cr	274.34Cr	296.88Cr
Net Debt	-25Cr	42Cr	24Cr	4.89Cr	6.03Cr
Debt Equivalent of Unfunded Proj. Benefit Obligation	43L	-	-	-	-
Debt Equivalent Oper. Leases	100.98Cr	14Cr	53Cr	53Cr	59Cr
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	-	-	-	-	-
Inventories - Work In Process, Total	-	-	-	-	-
Inventories - Finished Goods, Total	-	-	-	-	-
Land - (BS)	90.8L	90.8L	90.8L	90.8L	90.8L
Buildings, Total	26Cr	27Cr	27Cr	29Cr	30Cr
Machinery, Total	14Cr	17Cr	20Cr	23Cr	25Cr
Full Time Employees	1.66T	2T	2.1T	2.23T	2.5T

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-85Cr	-113.12Cr	-44Cr	-28Cr	31Cr
Depreciation & Amortization - CF	8.97Cr	8.56Cr	9.7Cr	5.67Cr	5.57Cr
Depreciation & Amortization, Total	8.97Cr	8.56Cr	9.7Cr	5.67Cr	5.57Cr
(Gain) Loss on Sale of Investments - (CF)	-5.57Cr	3.33Cr	1.69Cr	30.22L	23.06L
Stock-Based Compensation (CF)	17Cr	23Cr	22Cr	27Cr	35Cr
Other Operating Activities, Total	17Cr	28Cr	20Cr	15Cr	25Cr
Change In Accounts Receivable	-10Cr	-4.56Cr	-8.79Cr	-8.66Cr	-36Cr
Change In Inventories	-2.64Cr	-3.41Cr	1.84Cr	1.36Cr	84.74L
Change In Accounts Payable	8.82Cr	19Cr	8.08Cr	9.11Cr	7.51Cr
Change in Unearned Revenues	-5.04Cr	-6.59Cr	5.5Cr	-24Cr	-5.06Cr
Change in Other Net Operating Assets	-7.24Cr	-8.17Cr	-5.55Cr	32.29L	-12Cr
Cash from Operations	-64Cr	-54Cr	10Cr	-83.12L	52Cr
Capital Expenditure	-7.64Cr	-7.21Cr	-6.22Cr	-3.43Cr	-5.87Cr
Investment in Marketable and Equity Securities, Total	-19Cr	25Cr	-27Cr	-6.32Cr	50Cr
Other Investing Activities, Total	-43.64L	-1.32Cr	-44.38L	-1.93Cr	-21.5L
Cash from Investing	-27Cr	17Cr	-34Cr	-12Cr	44Cr
Long-Term Debt Issued, Total	50Cr	101.61Cr	-	-	65Cr
Total Debt Issued	50Cr	101.61Cr	-	-	65Cr
Long-Term Debt Repaid, Total	-	-88Cr	-	-	-119.26Cr
Total Debt Repaid	-	-88Cr	-	-	-119.26Cr
Issuance of Common Stock	25Cr	26Cr	15Cr	30Cr	25Cr
Repurchase of Common Stock	-	-	-	-	-
Other Financing Activities, Total	50Cr	3.1Cr	2.47Cr	-87.92L	-82.72L
Cash from Financing	124.71Cr	43Cr	17Cr	29Cr	-31Cr
Foreign Exchange Rate Adjustments	-90.18L	-74.3L	63.91L	-1.52Cr	3.49Cr
Net Change in Cash	32Cr	4.64Cr	-5.37Cr	15Cr	69Cr
Supplemental Items
Cash Interest Paid	2.47Cr	4.52Cr	3.21Cr	6.76Cr	22Cr
Cash Income Tax Paid (Refund)	-	-	-	1.44Cr	2.12Cr
Levered Free Cash Flow	9.71Cr	-40Cr	15Cr	20Cr	13Cr
Unlevered Free Cash Flow	19Cr	-31Cr	22Cr	29Cr	29Cr
Change In Net Working Capital	-45Cr	5.93Cr	-14Cr	-10Cr	37Cr
Net Debt Issued / Repaid	50Cr	14Cr	-	-	-55Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-12.56	-13.65	-4.78	-2.74	6.81
Return on Total Capital	-16.46	-18.77	-7.17	-4.19	9.55
Return On Equity %	-106.31	-526.14	232.4	362.29	73.28
Return on Common Equity	-106.31	-526.14	232.4	362.29	73.28
Margin Analysis
Gross Profit Margin %	83.4	83.73	83.02	85.62	81.64
SG&A Margin	83.16	74.29	43.52	43.39	32.6
EBITDA Margin %	-78.3	-71.39	-12.48	-5.35	15
EBITA Margin %	-83.93	-75.68	-15.43	-7.87	13.51
EBIT Margin %	-83.93	-75.68	-15.43	-7.87	13.51
Income From Continuing Operations Margin %	-101.01	-109.04	-24.08	-12.37	8.45
Net Income Margin %	-101.01	-109.04	-24.08	-12.37	8.45
Net Avail. For Common Margin %	-101.01	-109.04	-24.08	-12.37	8.45
Normalized Net Income Margin	-67.2	-61.28	-14.24	-10.41	5.48
Levered Free Cash Flow Margin	11.5	-38.87	8.01	8.8	3.47
Unlevered Free Cash Flow Margin	22.09	-29.48	12.16	12.75	7.72
Asset Turnover
Asset Turnover	0.24	0.29	0.5	0.56	0.81
Fixed Assets Turnover	1.17	1.41	2.5	3.17	5.3
Receivables Turnover (Average Receivables)	5.61	4.75	6.46	6.13	6.28
Inventory Turnover (Average Inventory)	1.73	1.57	2.85	3.86	8.46
Short Term Liquidity
Current Ratio	4.04	3.51	3.08	2.78	2.76
Quick Ratio	3.79	3.16	2.86	2.61	2.51
Operating Cash Flow to Current Liabilities	-0.92	-0.7	0.11	-0.01	0.36
Days Sales Outstanding (Average Receivables)	65.06	76.79	56.47	59.67	58.13
Days Outstanding Inventory (Average Inventory)	210.39	232.78	128.23	94.88	43.15
Average Days Payable Outstanding	151.24	148.06	103.6	84.22	54.3
Cash Conversion Cycle (Average Days)	124.21	161.51	81.1	70.33	46.98
Long Term Solvency
Total Debt/Equity	371.59	-1.65T	-1.22T	4.09T	376.19
Total Debt / Total Capital	78.8	106.45	108.96	97.61	79
LT Debt/Equity	358.39	-1.6T	-1.17T	3.86T	342.54
Long-Term Debt / Total Capital	76	103.1	105.04	92.1	71.93
Total Liabilities / Total Assets	83.86	104.46	105.76	98.42	84.11
EBIT / Interest Expense	-4.95	-5.03	-2.33	-1.25	1.99
EBITDA / Interest Expense	-3.74	-4.64	-1.33	-0.38	2.5
(EBITDA - Capex) / Interest Expense	-4.27	-5.1	-1.85	-0.63	2.27
Total Debt / EBITDA	-4.09	-3.61	-16.61	-50.36	4.7
Net Debt / EBITDA	0.47	-0.58	-1.51	-0.9	0.1
Total Debt / (EBITDA - Capex)	-3.58	-3.29	-11.99	-30.91	5.18
Net Debt / (EBITDA - Capex)	0.41	-0.53	-1.09	-0.55	0.11
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	71.31	22.88	76.23	22.97	65.19
Gross Profit, 1 Yr. Growth %	69.75	23.36	74.75	26.81	57.52
EBITDA, 1 Yr. Growth %	-16.7	12.03	-69.2	-47.3	-563.53
EBITA, 1 Yr. Growth %	-14.46	10.78	-64.06	-37.31	-383.56
EBIT, 1 Yr. Growth %	-14.46	10.78	-64.06	-37.31	-383.56
Earnings From Cont. Operations, 1 Yr. Growth %	-0.64	32.64	-61.08	-36.82	-212.79
Net Income, 1 Yr. Growth %	-0.64	32.64	-61.08	-36.82	-212.79
Normalized Net Income, 1 Yr. Growth %	-0.2	12.03	-59.04	-10.14	-186.94
Diluted EPS Before Extra, 1 Yr. Growth %	-3.54	29.11	-62.1	-38.18	-206.88
Accounts Receivable, 1 Yr. Growth %	93.89	19.84	37.75	23.65	91.85
Inventory, 1 Yr. Growth %	14.84	49.33	-30.87	-11.93	5.36
Net Property, Plant and Equip., 1 Yr. Growth %	3.84	0.68	-1.74	-4.39	2.04
Total Assets, 1 Yr. Growth %	6.93	-2.66	7.99	10.71	17.13
Tangible Book Value, 1 Yr. Growth %	-42.12	-126.9	39.45	-130.41	1.08T
Common Equity, 1 Yr. Growth %	-42.12	-126.9	39.45	-130.41	1.08T
Cash From Operations, 1 Yr. Growth %	4.35	-15.65	-119.24	-107.98	-6.41T
Capital Expenditures, 1 Yr. Growth %	8.54	-5.65	-13.67	-44.9	71.24
Levered Free Cash Flow, 1 Yr. Growth %	-112.5	-515.25	-136.34	91.09	-34.92
Unlevered Free Cash Flow, 1 Yr. Growth %	-125.75	-263.96	-172.7	59.8	0.05
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	96.01	45.08	47.16	47.21	42.53
Gross Profit, 2 Yr. CAGR %	90.18	44.71	46.82	48.86	41.34
EBITDA, 2 Yr. CAGR %	-15.34	-3.4	-41.26	-59.71	56.29
EBITA, 2 Yr. CAGR %	-13.15	-2.65	-36.9	-52.53	33.32
EBIT, 2 Yr. CAGR %	-13.15	-2.65	-36.9	-52.53	33.32
Earnings From Cont. Operations, 2 Yr. CAGR %	-1.9	14.8	-28.15	-50.41	-15.58
Net Income, 2 Yr. CAGR %	-1.9	14.8	-28.15	-50.41	-15.58
Normalized Net Income, 2 Yr. CAGR %	0.63	5.74	-32.26	-39.33	-11.61
Diluted EPS Before Extra, 2 Yr. CAGR %	-5.78	11.59	-30.03	-51.58	-18.69
Accounts Receivable, 2 Yr. CAGR %	114.87	52.43	28.48	30.51	54.02
Inventory, 2 Yr. CAGR %	23.8	30.95	1.6	-21.98	-3.67
Net Property, Plant and Equip., 2 Yr. CAGR %	6.54	2.25	-0.54	-3.07	-1.23
Total Assets, 2 Yr. CAGR %	23.33	2.02	2.53	9.34	13.87
Tangible Book Value, 2 Yr. CAGR %	-36.06	-60.54	-38.75	-34.88	89.12
Common Equity, 2 Yr. CAGR %	-36.06	-60.54	-38.75	-34.88	89.12
Cash From Operations, 2 Yr. CAGR %	51.81	-6.18	-59.71	-87.61	124.31
Capital Expenditures, 2 Yr. CAGR %	-26.18	1.2	-9.75	-31.03	-2.87
Levered Free Cash Flow, 2 Yr. CAGR %	-51.67	-27.96	22.83	-33.27	11.52
Unlevered Free Cash Flow, 2 Yr. CAGR %	-33.03	-35.03	9.17	-9.11	26.44
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	124.21	67.75	54.8	38.61	52.98
Gross Profit, 3 Yr. CAGR %	112.77	64.62	54.1	39.82	51.7
EBITDA, 3 Yr. CAGR %	-6.14	-7.05	-34.01	-43.35	-9.05
EBITA, 3 Yr. CAGR %	-4.54	-5.81	-30.16	-37.04	-13.87
EBIT, 3 Yr. CAGR %	-4.54	-5.81	-30.16	-37.04	-13.87
Earnings From Cont. Operations, 3 Yr. CAGR %	3.85	8.48	-19.95	-31.16	-34.78
Net Income, 3 Yr. CAGR %	3.85	8.48	-19.95	-31.16	-34.78
Normalized Net Income, 3 Yr. CAGR %	5.91	4.3	-22.92	-25.57	-31.6
Diluted EPS Before Extra, 3 Yr. CAGR %	-1.66	4.65	-22.13	-32.86	-36.95
Accounts Receivable, 3 Yr. CAGR %	119.56	76.87	47.37	26.85	48.39
Inventory, 3 Yr. CAGR %	53.1	31.78	5.83	-3.13	-13.76
Net Property, Plant and Equip., 3 Yr. CAGR %	31.77	4.55	0.9	-1.84	-1.4
Total Assets, 3 Yr. CAGR %	32.26	13.98	3.98	5.19	11.88
Tangible Book Value, 3 Yr. CAGR %	-23.27	-52.09	-39.9	-51.5	70.86
Common Equity, 3 Yr. CAGR %	-23.27	-52.09	-39.9	-51.5	70.86
Cash From Operations, 3 Yr. CAGR %	4.48	24.81	-44.67	-76.52	-1.07
Capital Expenditures, 3 Yr. CAGR %	-15.57	-19.89	-4.02	-23.44	-6.61
Levered Free Cash Flow, 3 Yr. CAGR %	-40.89	-1.02	-42.66	26.78	-33.82
Unlevered Free Cash Flow, 3 Yr. CAGR %	-26.53	-9.74	-32.55	15.39	-6.15
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	78.07	63.09	89.45	59.21	49.77
Gross Profit, 5 Yr. CAGR %	71.72	57.4	83.42	58.13	48.86
EBITDA, 5 Yr. CAGR %	10.06	8.69	-22.18	-33.47	-6.83
EBITA, 5 Yr. CAGR %	10.79	9.44	-19.11	-28.39	-9.55
EBIT, 5 Yr. CAGR %	10.79	9.44	-19.11	-28.39	-9.55
Earnings From Cont. Operations, 5 Yr. CAGR %	15.77	18.17	-10.38	-20.68	-18.23
Net Income, 5 Yr. CAGR %	15.77	18.17	-10.38	-20.68	-18.23
Normalized Net Income, 5 Yr. CAGR %	16.83	15.77	-11.43	-16.03	-18.58
Diluted EPS Before Extra, 5 Yr. CAGR %	8.49	11.39	-14.18	-23.11	-20.77
Accounts Receivable, 5 Yr. CAGR %	53.46	47.57	77.2	56.62	49.99
Inventory, 5 Yr. CAGR %	-	-	29.94	6.86	1.92
Net Property, Plant and Equip., 5 Yr. CAGR %	44.97	32.35	17.75	1.43	0.04
Total Assets, 5 Yr. CAGR %	23.6	12.2	19.45	12.1	7.83
Tangible Book Value, 5 Yr. CAGR %	-8.56	-38.28	-29.88	-45.83	-4.93
Common Equity, 5 Yr. CAGR %	-8.56	-38.28	-29.88	-45.83	-4.93
Cash From Operations, 5 Yr. CAGR %	15.84	7.17	-28.63	-50.46	-3.15
Capital Expenditures, 5 Yr. CAGR %	3.42	-7.11	-13.29	-24.55	-3.56
Levered Free Cash Flow, 5 Yr. CAGR %	-12.41	4.18	-20.8	-13.8	-30.2
Unlevered Free Cash Flow, 5 Yr. CAGR %	-0.2	-1.43	-13.92	-7.18	-16.92